News

A cross-sectional study uses epidemiological patterns to investigate these disparities, while also predicting the potential shift of these patterns by 2050.

The 13,400 square-foot Belgium site will expand the company’s branded standardized bioprocessing, cryopreservation, and distribution solution for the cell therapy market, with a focus on leukapheresis starting materials.

In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, explains how the use of blockchain technology will become more prominent moving forward.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, offers his observations as to how stakeholders are building out their networks.

The conference returns to Lyon, France and promises a timely and relevant agenda that attendees will resonate with.

One packaging aspect—the tape—is often overlooked, but is a valuable component of the shipping process.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, describes how events such as the East and Gulf Coast port strikes have brought to light the differences between branded and generic pharmaceuticals.

By 2050, study estimates that cancer incidence and mortality rates will nearly triple in low-Human Development Index countries, highlighting an urgent need for enhanced global cancer prevention, early detection, and treatment strategies to address growing disparities.

Digital transformation initiatives are often complex endeavors that can significantly impact the way organizations operate.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, forecasts the future of the pharma cold chain regarding technological advancements and changes in market dynamics.

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, discusses the significant increase in demand for sustainable practices and outlines the company's initiatives in this area.

JAMA study indicates Canada may have a more resilient drug supply chain or different thresholds for reporting and responding to issues compared with the United States.

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, explains why ultra-precise temperature control and customized logistics solutions are critical when it comes to biologics and personalized medicine.

Analysis finds that while basic Part D coverage costs have decreased by 4%, mid- and high-tier plans have seen hikes of 4% and 21%, respectively.

In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, describes the progression of expectations when it comes to the sector, specifically as it relates to new drug development.

With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.

Albert Thigpen, co-founder, Talentwise Consulting, explains how the specialty pharmacy sector has evolved over the years.

Are SDOHs associated with Medicare, Medicaid, and private insurer spending?

Albert Thigpen, co-founder, Talentwise Consulting, discusses the valuable buckets pertaining to the PBM space.

With the design of the new 360,000 square-foot building, the CDMO’s goal is to continue to modernize its Laupheim site.

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jeffrey Bernstein, director of cybersecurity and data privacy for Kaufman Rossin’s risk advisory services, forecasts how cyber threats could potentially evolve over the next decade.

How does it affect the likelihood of migration?

In the second part of this video interview with Pharma Commerce Editor Nicholas Saraceno, Jeffrey Bernstein, director of cybersecurity and data privacy for Kaufman Rossin’s risk advisory services, outlines some of the common cyber threats faced by healthcare companies.

Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses key takeaways of the breakout session.